Save time and get answers to complex questions with AI chat
Guselkumab patent expiration?When will tenofovir alafenide come off patent in canada?When will latisse patent expire?Combivent generic equivalent?Is it okay to take anti histamine when on statins?
See the DrugPatentWatch profile for Kisqali
Kisqali (ribociclib) is Novartis’ CDK4/6 inhibitor for HR+/HER2- breast cancer. Its sales are reported as net sales by Novartis and have grown to the multi‑billion range in recent years. Would you like the latest figure for: - a specific time frame (latest quarter or full year), - and in which currency (USD or CHF)? I can point you to the exact numbers from the latest Novartis results if you tell me the preferred time frame.
Other Questions About Kisqali :